N-(3-ethylphenyl)-N-[[3-[5-(1-fluoroethyl)-1,3,4-oxadiazol-2-yl]-1,2-oxazol-5-yl]methyl]ethanesulfonamide
C18H21FN4O4S — CID 156799462
Data last refreshed: (MolForge compound catalog, from PubChem)
About N-(3-ethylphenyl)-N-[[3-[5-(1-fluoroethyl)-1,3,4-oxadiazol-2-yl]-1,2-oxazol-5-yl]methyl]ethanesulfonamide
N-(3-ethylphenyl)-N-[[3-[5-(1-fluoroethyl)-1,3,4-oxadiazol-2-yl]-1,2-oxazol-5-yl]methyl]ethanesulfonamide (PubChem CID 156799462) has the molecular formula C18H21FN4O4S and a molecular weight of 408.46 g/mol. Its IUPAC name is N-(3-ethylphenyl)-N-[[3-[5-(1-fluoroethyl)-1,3,4-oxadiazol-2-yl]-1,2-oxazol-5-yl]methyl]ethanesulfonamide.
Molecular Properties
| Compound Name | N-(3-ethylphenyl)-N-[[3-[5-(1-fluoroethyl)-1,3,4-oxadiazol-2-yl]-1,2-oxazol-5-yl]methyl]ethanesulfonamide |
|---|---|
| PubChem CID | 156799462 |
| Molecular Formula | C18H21FN4O4S |
| Molecular Weight | 408.46 g/mol |
| Exact Mass | 408.13 |
| IUPAC Name | N-(3-ethylphenyl)-N-[[3-[5-(1-fluoroethyl)-1,3,4-oxadiazol-2-yl]-1,2-oxazol-5-yl]methyl]ethanesulfonamide |
| SMILES | CCc1cccc(N(Cc2cc(-c3nnc(C(C)F)o3)no2)S(=O)(=O)CC)c1 |
| InChI | InChI=1S/C18H21FN4O4S/c1-4-13-7-6-8-14(9-13)23(28(24,25)5-2)11-15-10-16(22-27-15)18-21-20-17(26-18)12(3)19/h6-10,12H,4-5,11H2,1-3H3 |
| InChIKey | SCZDYGVMJKHQEN-UHFFFAOYSA-N |
| XLogP | 3.67 |
| TPSA | 102.33 Ų |
| H-Bond Donors | |
| H-Bond Acceptors | 7 |
| Rotatable Bonds | 8 |
| Heavy Atoms | 28 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 408.46 |
| LogP ≤ 5 | 3.67 |
| H-Bond Donors ≤ 5 | 0 |
| H-Bond Acceptors ≤ 10 | 7 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 156799462 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.